Atrial Fibrillation Market, By Procedure (Pharmacological (Anti-arrhythmic, Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery, Electric Cardioversion)), and By Region (North America, Latin America, Europe, Asia Pacific, Midd

Atrial Fibrillation Market, By Procedure (Pharmacological (Anti-arrhythmic, Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery, Electric Cardioversion)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & AFrica) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Atrial Fibrillation is also known as A-fib or AF, is an irregular heartbeat exemplified by rapid and abnormal beating of the heart. It is linked with an elevated risk of heart failure, stroke, and dementia. Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. High prevalence of atrial fibrillation along with increasing product approvals during the forecasted period is expected to assist the growth of the market. Furthermore, major players in the global atrial fibrillation market are focused on R&D to expand their product portfolio which is also expected to drive the market during the forecast period.
Key features of the study:
This report provides in-depth analysis of the Global Atrial Fibrillation market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global Atrial Fibrillation market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Inc., Johnson and Johnson Ltd., and Abbott Laboratories.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global Atrial Fibrillation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Atrial Fibrillation market
Detailed Segmentation:
Global Atrial Fibrillation Market, By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
Global Atrial Fibrillation Market, By Region:
North America
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
By Country
U.S.
Canada
Latin America
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion s
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Procedure:
Pharmacological
Anti-arrhythmic
Anti-coagulant
Non-Pharmacological
Catheter Ablation Procedures
Maze surgery
Electric Cardioversion
By Country
North Africa
Central Africa
South Africa
Company Profiles
AtriCure, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Biosense Webster, Inc.
Boehringer Ingelheim GmbH
Boston Scientific Corporation
Bristol-Myers Squibb Corporation
CardioFocus, Inc.
Endoscopic Technologies, Inc.
Sanofi Aventis, Inc.
Johnson and Johnson Ltd.
Abbott Laboratories
“*” marked represents similar segmentation in other categories in the respective section.